| First Author | Mirzaei HR | Year | 2016 |
| Journal | Cancer Lett | Volume | 380 |
| Issue | 2 | Pages | 413-23 |
| PubMed ID | 27392648 | Mgi Jnum | J:234919 |
| Mgi Id | MGI:5792440 | Doi | 10.1016/j.canlet.2016.07.001 |
| Citation | Mirzaei HR, et al. (2016) Prospects for chimeric antigen receptor (CAR) gammadelta T cells: A potential game changer for adoptive T cell cancer immunotherapy. Cancer Lett 380(2):413-23 |
| abstractText | Excitement is growing for therapies that harness the power of patients' immune systems to combat their diseases. One approach to immunotherapy involves engineering patients' own T cells to express a chimeric antigen receptor (CAR) to treat advanced cancers, particularly those refractory to conventional therapeutic agents. Although these engineered immune cells have made remarkable strides in the treatment of patients with certain hematologic malignancies, success with solid tumors has been limited, probably due to immunosuppressive mechanisms in the tumor niche. In nearly all studies to date, T cells bearing alphabeta receptors have been used to generate CAR T cells. In this review, we highlight biological characteristics of gammadelta T cells that are distinct from those of alphabeta T cells, including homing to epithelial and mucosal tissues and unique functions such as direct antigen recognition, lack of alloreactivity, and ability to present antigens. We offer our perspective that these features make gammadelta T cells promising for use in cellular therapy against several types of solid tumors, including melanoma and gastrointestinal cancers. Engineered gammadelta T cells should be considered as a new platform for adoptive T cell cancer therapy for mucosal tumors. |
